1
|
Affiliation(s)
- John W. Roman
- Department of Dermatology, Walter Reed National Military Medical Center, Bethesda, Maryland
- Correspondence to: John W. Roman, MD, 22 Grove Ridge Ct, North Bethesda, MD 20852.22 Grove Ridge CtNorth BethesdaMD20852
| | - Michelle A. Ojemuyiwa
- Department of Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland
| | - Lisa M. Cordes
- National Institutes of Health, Clinical Center Pharmacy Department, Bethesda, Maryland
| | - Ravi A. Madan
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
| | - Leonard Sperling
- Department of Dermatology and Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| |
Collapse
|
2
|
Mertz AT, Ojemuyiwa MA. A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature. Case Rep Oncol 2017; 9:847-853. [PMID: 28101034 PMCID: PMC5216239 DOI: 10.1159/000452655] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 10/18/2016] [Indexed: 12/19/2022] Open
Abstract
Poorly differentiated neuroendocrine carcinomas (NECs) are rare tumors that can arise anywhere along the gastrointestinal tract. They often present in advanced stage and portend a poor prognosis when compared to adenocarcinomas of the same stage. Characterization of these tumors is best accomplished with tissue biopsy, as peripheral tumor markers commonly used in NECs are of little utility. Therapeutic strategies often involve chemotherapeutic regimens that have been used to treat small-cell lung cancer. Recent studies have shown that programmed death-ligand 1 (PD-L1) expression within poorly differentiated NECs is a poor prognostic indicator. However, PD-L1 expression may represent a possible target for immunotherapy drugs, often called checkpoint inhibitors, such as anti-PD-1 inhibitors.
Collapse
Affiliation(s)
- Andrew T Mertz
- Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Michelle A Ojemuyiwa
- Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA
| |
Collapse
|
3
|
Karzai F, Madan RA, Ning YM, Theoret MR, Arlen PM, Parnes HL, Ojemuyiwa MA, Strauss J, Dawson NA, McLeod DG, Harold N, Couvillon A, Cordes LM, Chen C, Steinberg SM, Sissung TM, Price DK, Gulley JL, Figg WD, Dahut WL. Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.2_suppl.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
272 Background: AA pts experience greater prostate cancer (PC) incidence and mortality compared to Caucasian (C) pts but are underrepresented in clinical trials (CTs). Greater representation of AAs is required to explore differences in clinical benefit in advanced disease where recent data has reaffirmed the role of D. Methods: In a retrospective analysis, baseline characteristics, Gleason score (GS), ECOG PS, number of cycles (cys), maximum prostate-specific antigen (PSA) declines, radiographic responses, overall survival (OS) and progression-free survival (PFS) were captured in 2 recent D based CTs. Results: Of 136 pts, 28 (21%) self-identified as Black or AA. Median age of AA pts is 66 (50-78 yrs). Median GS is 8 (5-10). Median ECOG PS is 1 (0-2). 15 pts have bone and soft tissue disease; 13 pts have bone only disease. Median number of cys is 28.5 (1-63). Of 27 evaluable pts, 26 had PSA declines (-26 to -99%). Radiographic responses include 11 (39%) partial responses and 16 (57%) pts with stable disease. Median OS for AAs is 29.0 months (mos) (95% CI: 20.9-34.7 mos); median PFS is 21.5 mos (95% CI: 13.7-28.9 mos). Median OS for all non-AA pts is 24.8 mos (95% CI: 21.8-29.5 mos); median PFS is 16.1 mos (95% CI: 14.1-20.1 mos). The VEGF-634G > C SNP, associated with a more aggressive phenotype of PC, was evaluated in 54 pts. No evidence was found that genotype frequency varies between C and AA pts. Conclusions: In this analysis, AA pts did not have inferior OS (29 mos) or PFS (21.5 mos) outcomes compared to non-AA pts (24.8, 16.1 mos). Further analysis from larger studies is required to determine differential benefits of D for AA pts compared to non-AA pts. Clinical trial information: NCT00089609, NCT00942578.
Collapse
Affiliation(s)
- Fatima Karzai
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Yang-Min Ning
- U.S. Food and Drug Administration, Silver Spring, MD
| | | | - Philip M. Arlen
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Howard L. Parnes
- Division of Cancer Prevention, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Julius Strauss
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | | | - Nancy Harold
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Anna Couvillon
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Clara Chen
- Department of Nuclear Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Seth M. Steinberg
- Biostatistics and Data Management Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Tristan M. Sissung
- Molecular Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Douglas K. Price
- Genitourinary Malignancies Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - James L. Gulley
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William Douglas Figg
- Clinical Pharmacology Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William L. Dahut
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| |
Collapse
|
4
|
Ojemuyiwa MA, Madan RA, Dahut WL. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs 2014; 19:459-70. [PMID: 25345821 DOI: 10.1517/14728214.2014.969239] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
INTRODUCTION Prostate cancer (PCa) is the most frequently diagnosed, non-cutaneous malignancy in Western countries. Until recently, few therapeutic options were available for patients with advanced PCa. Although these treatments may delay progression of disease, none are curative. Therefore, research continues to investigate other treatments for advanced PCa. Tyrosine kinase inhibitors (TKIs) have been extensively studied as a treatment for multiple malignancies and may represent an additional strategy. In addition to limiting cellular proliferation and metastasis, there is also growing interest in using these treatments to impact the bone microenvironment and reduce associated morbidity from PCa. AREAS COVERED Several TKIs have been evaluated in the preclinical setting in advanced PCa. Targets reviewed include the epidermal growth factor family, VEGF receptor, c-Src family kinases, platelet-derived growth factor and c-Met. EXPERT OPINION Despite strong biological rationale for the use of TKIs therapy for the treatment of PCa, Phase III clinical trials have produced disappointing results. As TKI strategies move forward, the failures of past trials need to be better understood. New approaches with these treatments will also have to take into account modern anti-androgens and a treatment landscape that now includes immunotherapy.
Collapse
Affiliation(s)
- Michelle A Ojemuyiwa
- Clinical Fellow,National Cancer Institute, Medical Oncology Branch , 9000 Rockville Pike Bldg 10, Rm 12N226, Bethesda, MD 20892 , USA
| | | | | |
Collapse
|
5
|
Karzai F, Shah AA, Ojemuyiwa MA, Madan RA, Apolo AB, Dawson NA, Arlen PM, Theoret MR, Wright JJ, Chen C, Trepel JB, Couvillon A, Chun G, Harold N, Steinberg SM, Price DK, Gulley JL, Figg WD, Dahut WL. A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Avani Atul Shah
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Ravi Amrit Madan
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | | | - Philip M. Arlen
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Marc Robert Theoret
- Clinical Center/National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Clara Chen
- Department of Nuclear Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Jane B. Trepel
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
| | - Anna Couvillon
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Guinevere Chun
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Nancy Harold
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Seth M. Steinberg
- Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Douglas K. Price
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - James L. Gulley
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William Douglas Figg
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William L. Dahut
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| |
Collapse
|
6
|
Ojemuyiwa MA, Karzai F, Shah AA, Theoret MR, Harold N, Chun G, Figg WD, Apolo AB, Price DK, Madan RA, Gulley JL, Dahut WL. A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Avani Atul Shah
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Marc Robert Theoret
- Clinical Center/National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Nancy Harold
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Guinevere Chun
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William Douglas Figg
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Douglas K. Price
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Ravi Amrit Madan
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - James L. Gulley
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William L. Dahut
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| |
Collapse
|
7
|
Ojemuyiwa MA, Karzai FH, Shah AA, Theoret MR, Harold N, Chun G, Couvillon A, Apolo AB, Price DK, Madan RA, Figg WD, Gulley JL, Dahut WL. A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.4_suppl.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
218 Background: Trebananib is an angiopoietin1/2 antagonist peptibody. Androgens stimulate expression of VEGF via activation of hypoxia inducible factor-a (HIFa). Androgen deprivation therapy (ADT) is associated with lower HIF1a gene expression in prostate cancer tissue. Dual targeting of the androgen and angiogenic axis represents a potential synergistic anti-angiogenic therapeutic approach in metastatic castration resistant prostate cancer (mCRPC). In this preliminary safety study we hypothesize that trebananib in combination with abiraterone will have a favorable tolerability and efficacy profile. Methods: Patients with mCRPC were treated with abiraterone 1000mg daily and prednisone 5 mg twice daily. Trebananib was administered intravenously every week, in escalating doses from 15mg/kg to 30mg/kg on days 1, 8, 15, and 22 every 28-days. Results: A total of 9 patients were enrolled. Three of nine patients had prior chemotherapy. The median age was 63.8 (63-71yrs). No dose limiting toxicities were observed. The most common grade ≥ 2 toxicities included limb edema (3/9), hyperglycemia (1/9), gastrointestinal (2/9), fatigue (2/9), hypertension (1/9), confusion (1/9), weight gain (1/9) and insomnia (2/9). 5/9 of patients had an overall PSA decline of >30%. 8/9 patients were evaluable for response. Prior chemotherapy patients were on study for 1 and 3 months. No prior chemotherapy patients were treated for 1, 6, 9, 10, 10, and 17 months. Conclusions: Trebananib in combination with abiraterone is well tolerated and displayed an acceptable safety profile in patients with mCRPC. Based on this safety data a randomized phase II study randomizing chemotherapy-naïve mCRPC patients to either abiraterone/prednisone plus AMG 386 at 30mg/kg or abiraterone/prednisone is currently accruing at the NCI. Clinical trial information: NCIT01553188.
Collapse
Affiliation(s)
| | - Fatima H. Karzai
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Avani Atul Shah
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Marc Robert Theoret
- Clinical Center/National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Nancy Harold
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Guinevere Chun
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Anna Couvillon
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Douglas K. Price
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Ravi Amrit Madan
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William Douglas Figg
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - James L. Gulley
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William L. Dahut
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| |
Collapse
|
8
|
Karzai FH, Shah AA, Ojemuyiwa MA, Madan RA, Apolo AB, Dawson NA, Arlen PM, Theoret MR, Wright JJ, Chen C, Trepel JB, Couvillon A, Chun G, Harold N, Steinberg SM, Price DK, Gulley JL, Figg WD, Dahut WL. A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.4_suppl.108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
108 Background: Cabozantinib (C) is a multikinase inhibitor of c-Met, vascular endothelial growth factor receptor two and RET. C has shown activity in metastatic castrate resistant prostate cancer (mCRPC), with resolution of bone lesions on bone scan (BS), regression of soft tissue/visceral disease (STD), reductions in circulating tumor cells and bone biomarkers. Combining docetaxel (D) with other agents, without overlapping toxicities, can target different cellular signaling pathways necessary for tumor survival. Methods: Patients (pts), with no prior D for CRPC, receive a fixed dose of D (75 mg/m2 IV day one of each 21 day cycle) and prednisone (P) (5 mg po q12 hours) with C at three escalating dose levels: 20 mg, 40 mg, or 60 mg (all po daily). Using a standard three-plus-three design, three to six pts are treated at each dose level until the maximum tolerated dose (MTD) has been defined. Results: Thirteen pts have been accrued; four on dose level one, six on dose level two, and three on dose level three. Median age 69 (45 to 84). Four pts have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of zero and nine pts have a PS of one. Median Gleason score is nine (7 to 10). Median on-study prostate-specific antigen (PSA) is 129.2 ng/mL (0.01-508.5 ng/mL). Median cycles is six (1 to 17). Grade 1 adverse events (AEs), possibly related to C; dysgeusia (4/12), oral mucositis (4/12), increased ALT (3/12), and epistaxis (3/12). Grade 2 AEs; nausea (2/12), hand/foot syndrome (2/12), fatigue (2/12), dysgeusia (2/12), oral mucositis (2/12), hypophosphatemia (2/12), and anemia (2/12). Grade 3 AE is hypophosphatemia (2/12). Grade 4 AE is neutropenia (1/12). MTD of C is 60 mg. Of nine evaluable pts, six have bone only disease. Of these six, three pts have PSA declines of less than 30% with improvement on BS (two pts) or stable BS (one pt). The other three pts have PSA declines of greater than 30% and bone scan improvement. Three pts have STD and bone disease; one patient had a PSA decline of greater than 30% with improvement on BS and SD by CT scan. One patient had an increase in PSA of less than 30% with improvement on BS and CT. The third pt had PD by CT and an increase in PSA equal to 30%. PFS probability at six months is 90.0% and is 67.5% at eight months and beyond. Conclusions: The addition of C to D and P, has an acceptable toxicity profile. CT scan and BS improvements did not correlate with PSA declines in all pts. An expansion cohort will combine D plus P with C at the MTD (60 mg) to determine clinical benefit. Clinical trial information: NCT01683994.
Collapse
Affiliation(s)
- Fatima H. Karzai
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Avani Atul Shah
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | - Ravi Amrit Madan
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | | | | | - Philip M. Arlen
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Marc Robert Theoret
- Clinical Center/National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - John Joseph Wright
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Clara Chen
- Department of Nuclear Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Jane B. Trepel
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Anna Couvillon
- Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Guinevere Chun
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Nancy Harold
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - Seth M. Steinberg
- Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Douglas K. Price
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - James L. Gulley
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William Douglas Figg
- Molecular Pharmacology Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD
| | - William L. Dahut
- National Cancer Institute at the National Institutes of Health, Bethesda, MD
| |
Collapse
|